Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Current Attitude - another episode---BillW
12
Apr 11, 2008 07:42AM
3
Apr 11, 2008 08:06AM

I agree completely.  We now have the very personal who is appointed to represent us acknowledging that what you see is what you get, in his opinion.  Investors were unhappy because Biajj wasn't speaking, now he is and investors don't believe him.  Say what? 

 

I've really got to step back and revaluate the situation.  After speaking, in detail, with my father-in-law I've become much more suspicious of our circumstance.  Since he is the chairman of a very large public company and also one that is involved in multiple NDA's per quarter, I strongly value his input and opinion.  He insists that no NDA can triumph the responsibility of the company to it's shareholders.  The ability of the investor to make an informed decision can only occur when the company is dispersing the necessary information for that to happenr.  Although he acknowledged that an NDA can make that tricky, it CANNOT be written and or enforced in a way that would hurt shareholders one way or the other.  Mr. Goerner is certainly wording the PR's to sound as if the J3 settlement is reflected.  If that is in fact not the case, I believe PTSC will find themselves facing legal action from shareholders. 

 

My attitude is rapidly changing.  I am becoming disgusted with what I see.  Some of you can say what you will but, the information that  flowed from PTSC and TPL over the last year was certainly ment to make outsiders believe big things were happening behind the scenes.  If there are still unresolved issues looming, than it is not possible for shareholders to make an informed decision.  I believe that Biajj is correct otherwise, I am of the belief that Mr. Goerner has violated his fiduciary duties along with all the BOD members.

Share
New Message
Please login to post a reply